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1  | INTRODUC TION
Cutaneous melanoma makes up approximately 4% of skin cancers, 
yet it is responsible for more than 70% of skin cancer‐related deaths 
(Sample & He, 2018). Somatic melanoma genetics are complex with 
tumors exhibiting high mutational load mostly attributed to UV‐
induced DNA damage (Hodis et al., 2012). New germline genetic 
variants and genes contributing to melanoma susceptibility and 
progression are continually being discovered (Amos et al., 2011; 
Barrett et al., 2011; Bishop et al., 2009). Recently, genome‐wide asso‐
ciation studies (GWAS) have linked rs45430 SNP, a major T to minor 
C allele change, intronic to MX2 (myxovirus resistance 2) gene with 
reduced risk to cutaneous melanoma, and multiple primary tumors 
(Barrett et al., 2011; Gibbs et al., 2015). However, the functional role 
of this SNP or MX2 gene itself in the tumorigenesis has so far not 
been elucidated. MX2 protein is a dynamin‐like GTPase2 identified 
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Abstract
MX2 protein is a dynamin‐like GTPase2 that has recently been identified as an in‐
terferon‐induced restriction factor of HIV‐1 and other primate lentiviruses. A single 
nucleotide polymorphism (SNP), rs45430, in an intron of the MX2 gene, was previ‐
ously reported as a novel melanoma susceptibility locus in genome‐wide association 
studies. Functionally, however, it is still unclear whether and how MX2 contributes 
to melanoma susceptibility and tumorigenesis. Here, we show that MX2 is differen‐
tially expressed in melanoma tumors and cell lines, with most metastatic cell lines 
showing lower MX2 expression than primary melanoma cell lines and melanocytes. 
Furthermore, high expression of MX2 RNA in primary melanoma tumors is associated 
with better patient survival. Overexpression of MX2 reduces in vivo proliferation 
partially through inhibition of AKT activation, suggesting that it can act as a tumor 
suppressor in melanoma. However, we have also identified a subset of melanoma cell 
lines with high endogenous MX2 expression where downregulation of MX2 leads 
to reduced proliferation. In these cells, MX2 downregulation interfered with DNA 
replication and cell cycle processes. Collectively, our data for the first time show that 
MX2 is functionally involved in the regulation of melanoma proliferation but that its 
function is context‐dependent.
K E Y W O R D S
cell cycle, melanoma‐specific survival, MX2, PI3K/AKT, SNP
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as an interferon (IFN)‐induced restriction factor for several primate 
lentiviruses including HIV‐1 (Buffone, Schulte, Opp, & Diaz‐Griffero, 
2015; Goujon et al., 2013). Humans possess two MX genes, MX1 and 
MX2, with a high level of homology (Haller, Staeheli, Schwemmle, & 
Kochs, 2015). While MX1 protein is mainly induced after type I IFN 
(IFNα/β) stimulation during the antiviral response (Haller & Kochs, 
2010; Kim, Shenoy, Kumar, Bradfield, & MacMicking, 2012), MX2 
can be expressed at significant levels even in the absence of IFN 
(King, Raposo, & Lemmon, 2004). Unlike MX1, MX2 has an extended 
N‐terminal domain and exists as two isoforms. While the longer 
78 kDa isoform displays antiviral activity and is associated with the 
nuclear envelope, the shorter 76 kDa isoform is cytoplasmic with‐
out clearly defined cellular activity to date (Haller et al., 2015). MX2 
found in association with nuclear pores contributes to the regulation 
of viral DNA nuclear import and/or integration into the host cell ge‐
nome (Kane et al., 2013). One previous study suggested that MX2 
could have additional, viral‐independent cellular functions including 
regulation of cell cycle progression (King et al., 2004).
Here, we show for the first time, to best of our knowledge, that 
MX2 is functionally involved in cancer‐related processes in mela‐
noma. It is differentially expressed in melanoma tumors and cell lines, 
and it is a predictor of better patient survival. Interestingly, our data 
further show that MX2 function is complex, with both tumor‐sup‐
pressive and oncogenic features depending on the cellular context.
2  | MATERIAL S AND METHODS
2.1 | Cell lines and culture conditions
Primary human melanocytes (NHM9, NHM134, and NHM160) were 
isolated and cultured as previously described (Magnussen et al., 2012). 
Metastatic melanoma cell lines (MM) were established from melanoma 
patients treated at the Norwegian Radium Hospital, Oslo University 
Hospital as described in Flørenes et al., (2019). Melanoma cells 
were cultured in RPMI 1,640 medium (BioWhittaker) supplemented 
with 5% fetal bovine serum (FBS, Sigma) and 2 mM/L L‐glutamine 
(GibcoBRL) and maintained at 37°C in a humidified 5% CO2 atmos‐
phere. Primary melanocytes were grown in 254CF melanocyte media 
purchased from Gibco Life Technologies supplemented with calcium 
chloride, HMGS‐2 (human melanocytes growth supplement‐2), and 
10 ng/ml PMA. HEK293T cells (Clontech) were maintained in 4.5 g/L 
glucose, 4 mM L‐glutamine Dulbecco's modified Eagle's medium (cat. 
no BE12‐604F/U1; Lonza BioWhittaker) supplemented with 10% FBS, 
and 25 mM HEPES (cat. no H0877, Sigma‐Aldrich).
2.2 | siRNA knockdown
Described in the Supporting Information Data S1.
2.3 | Double thymidine block
Cells were synchronized at G1/S using a double thymidine block. 
At approximately 30% confluency, MM382 cells were subjected to 
culturing media supplemented with 2 mM thymidine for 16 hr (first 
block). Afterward, thymidine was washed off twice with PBS and 
cells were allowed to grow for 8 hr in normal conditions. Thymidine 
at final concentration of 2 mM was added for additional 15 hr before 
final release. Cells were collected at 0‐, 2‐, 4‐, 6‐, 8‐, 10‐, and 12‐hr 
time points after release.
2.4 | Cell viability
Two x 105 cells per well were seeded into 6‐well plates 24 hr be‐
fore treatment with siRNA. Cells were trypsinized and collected, 
and the total number was counted after 72 hr of treatment with 
siRNA. Viability values are presented as a mean percentage ± SE 
of three independent experiments normalized to the negative con‐
trol siRNA.
2.5 | RNA sequencing and analysis
The RNA‐seq files (fastq) prior to analysis were treated with 
Trimmomatic‐0.38 (Bolger, Lohse, & Usadel, 2014) to remove se‐
quence adapters. After trimming, the reads were (quasi)‐mapped 
directly to the transcriptome using human (GRCh38, Ensemble ver‐
sion 94), Salmon software (Patro, Duggal, Love, Irizarry, & Kingsford, 
2017). The DESeqDataSet was constructed by importing transcript 
abundance estimates from Salmon using the R txtimport package 
(Soneson et al., 2015), differentially expressed genes detected by R 
DESeq2 package (Love, Huber, & Anders, 2014). For the selection of 
differently expressed genes, a significance threshold based on ad‐
justed p‐value <.01 was applied. To further strengthen the selection, 
significantly (p < .01) expressed genes from three groups, combined 
(knockout 1 and knockout 2) and individually, were compared. From 
these, a core of 520 genes was selected based on overlapping ex‐
pression between the groups.
2.6 | Data
Sequence data are stored at Services for Sensitive Data (TSD)—
University of Oslo. Access can be arranged by contacting the cor‐
responding author (Ana S.) upon request. Graphical presenstations: 
Heatmaps were constructed using aheapmap function in R package 
Significance
The study provides the first evidence that antiviral MX2 
gene is associated with the tumorigenesis process in mela‐
noma. It has an IFN independent role in the regulation of cell 
cycle and the PI3K/AKT pathway. However, MX2 function 
is clearly cell type‐ and context‐dependent. Our findings are 
adding a functional explanation to previous genome‐wide 
association studies that reported an association between 
MX2 gene and reduced risk for melanoma.
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NMF (Gaujoux & Seoighe, 2010). The enrichGO function in the R 
package Clusterprofiler (Yu, Wang, Han, & He, 2012) was used for 
the GO over‐representation plots.
2.7 | Incucyte growth rate assessment
Cells overexpressing MX2 and GFP as a control were seeded into 
24‐well plate at a density of 25,000 cells per well. Cell proliferation 
was measured by a confluence assay using IncuCyteTM FLR (Essen 
Instruments) live‐cell imaging system. Phase‐contrast images were 
generated every 3 hr over a period of 3 days (for melanoma cells) 
or 4 days (for melanocytes). Cell proliferation was determined by 
analyzing cell confluence over time. The experiment was repeated 
three times in triplicate. Confluence values were normalized to an 
initial time point; data are presented as a mean value at a given time 
point ± SE.
2.8 | Cytoplasmic and nuclear fractionation
NE‐PER Nuclear and Cytoplasmic Extraction Reagent kit (cat. no. 
78833; Thermo Fisher Scientific) was used to isolate cytoplasmic 
and nuclear proteins. Isolation was performed according to the man‐
ufacturer's instructions. Halt Protease Inhibitor Cocktail (cat. no. 
87785; Thermo Fisher Scientific) was added to the CER I and NER 
extraction reagents before use.
2.9 | Flow cytometric analysis
For cell cycle analysis, 2 × 105 cells per well were seeded into 6‐well 
plates 24 hr before treatment with siRNA. Forty‐eight hours after 
transfection, cells were harvested by trypsinization, washed twice 
in ice‐cold PBS, and fixed resuspending cell pellets in 1 ml 70% ice‐
cold methanol. Fixated cells were stained with a ready‐to‐use DNA 
Labelling Solution (Cytognos, cat. no. CYT‐PIR‐25). Flow cytometric 
experiments were performed on BD FACSCaliburTM Flow cytometer 
(BD Biosciences). Data were analyzed with FlowJo v.7.6.1 software 
(Treestar Inc. Ashland).
2.10 | Quantitative real‐time PCR
Described in the Supporting Information Data S1.
2.11 | Rs45430 SNP genotyping
qPCRs were performed in duplicate in 96‐well plates. Five nano‐
gram of genomic DNA (gDNA) was mixed with TaqMan Genotyping 
Master Mix (cat. no 4371353; Applied Biosystems) and TaqMan 
SNP Genotyping Assay (cat. no 4351379, assay ID C_2564407_10; 
Applied Biosystems) specific for rs45430 polymorphism. PCRs 
were performed on a QuantStudioTM5 Real‐Time PCR system 
(Applied Biosystems, Thermo Fisher Scientific) running the fol‐
lowing program: (a) enzyme activation at 95ºC for 10 min, (b) 40 
cycles of PCR at 95ºC for 15 s, and 60ºC for 1 min. Genotypes of 
the samples were determined from the allelic discrimination and 
amplification plots.
2.12 | Generation of MX2 and GFP 
expression constructs
MX2 cDNA was purchased from OriGene, catalog no. SC127459. 
Entry vector encoding GFP—pENTRY‐GFP—was a gift from William 
Hahn (Addgene plasmid #15301). A destination vector pLenti‐
CMV‐Puro‐DEST (w118‐1) was a gift from Eric Campeau and Paul 
Kaufman; Addgene plasmid #17452. pCW57.1 construct was a gift 
from David Root; Addgene plasmid #41393. Detailed procedures for 
plasmid construction are described in the Supporting Information 
Data S1.
2.13 | Lentivirus production and generation of 
stable cell lines
Described in the Supporting Information Data S1.
2.14 | In vivo animal studies
WM983b cells (2 × 106) stably expressing MX2 or GFP diluted in 
200 µl serum‐free RPMI‐1640 media were subcutaneously injected 
in the right flank of nude mice (athymic nude foxn1 nu). Tumor sizes 
were measured once a week using a caliper, and the volume V was 
calculated as follows: V = W2 × L × 0.5 (where W and L are tumor 
width and length, respectively). The experimental protocol was 
evaluated and approved by the National Animal Research Authority 
and conducted in accordance with regulations of the European 
Laboratory Animals Science Association.
2.15 | Immunoblotting
Immunoblotting was performed as previously described (Magnussen 
et al., 2012) with few modifications. Cells were lysed with ice‐
cold NP‐40 lysis buffer supplemented with phosphatase in‐
hibitor (4906837001, Roche Diagnostics) and protease inhibitor 
(4693124001, Roche Diagnostics). Proteins were resolved on 4%–
20% or 10% gels (Bio‐Rad) by SDS‐PAGE electrophoresis. List of an‐
tibodies used is presented in Table S1. Visualization was performed 
with SuperSignal West Dura Chemiluminescence kit (Pierce).
2.16 | Clinical melanoma specimens for IHC
Formalin‐fixed, paraffin‐embedded tissue from 42 benign nevi, 154 
primary melanomas, and 60 metastases was examined for expression 
of MX2 protein. Clinical follow‐up was available for all patients, 72 
male and 82 female, with the mean age of 55.6 (range 19–97). The fol‐
low‐up period ranged from 1 to 361 months (mean = 104.8 months, 
median = 126.5 months). The Regional Committee for Medical 
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Research Ethics South of Norway (S‐06151) and The Social and 
Health Directorate (06/2733) approved the current study protocol.
2.17 | Immunohistochemical analysis
Immunohistochemical staining procedure is described in the 
Supporting Information Data S1. Semiquantitative classification 
was used to describe staining intensity (absent = 0; weak = 1; 
moderate = 2; strong = 3) and percentage of positive tumor cell 
(absent = 0; 0%–25% = 1; 25%–50% = 2; 50%–75% = 3; >75% = 4). 
By multiplying intensity score with percentage positive cell score, 
a total immunoreactivity score was calculated ranging from 0 
to 12. Immunoscore >3 was considered as high in the statistical 
analyses.
2.18 | Mitotic rate classification
Mitotic rate was histologically assessed by count of mitoses per 
mm2, also described in Poźniak et al., (2019).
2.19 | Statistical analysis
Statistical analysis was performed applying SPSS package version 
18, (SPSS Inc.) and Stata 14.2. Comparison between variables was 
performed using the chi‐square test or Fisher exact test. Two‐tailed 
paired Student's t test and Wilcoxon matched‐pairs signed‐rank test 
was used for the evaluation of in vitro results. A p value of less than 
.05 was considered statistically significant. In the Leeds Melanoma 
Cohort (LMC) (Nsengimana et al., 2018), the relationship between 
MX2 expression and mean tumor thickness was evaluated using 
Mann–Whitney two‐sample test. Melanoma‐specific survival (MSS) 
analysis of MX2 gene expression was performed using univariate 
Cox proportional hazard model in the whole dataset, and in each of 
the immune subgroups (low, intermediate, and high). The generation 
of the immune subgroups was defined in Poźniak et al., (2019) in 
which immune cell infiltration was imputed using the expression of 
genes reported to be exclusively expressed by each immune cell. The 
Kaplan–Meier curve was generated after dichotomizing MX2 ex‐
pression by median (high and low). The difference of MX2 expression 
was tested among the three immune subgroups using Kruskal–Wallis 
and Dunnett's test. Kaplan–Meier survival estimates and log‐rank 
tests were used to evaluate the survival data.
2.20 | Transcriptomic data
Generation of gene expression data from 703 FFPE tumors of the 
LMC was as described elsewhere (Nsengimana et al., 2018). These 
data were deposited in the European Genome‐phenome Archive 
(EGA), accession number EGAS00001002922. Gene expression 
from metastatic melanomas in The Cancer Genome Atlas (TCGA) 
was downloaded from c‐bioportal (http://www.cbiop ortal.org/) and 
was classified into the three immune subgroups as reported previ‐
ously (Poźniak et al., 2019).
3  | RESULTS
3.1 | MX2 is constitutively and differentially 
expressed in melanoma tumors and cell lines
To investigate the potential role of MX2 in melanoma, we first exam‐
ined its RNA and protein expression in a panel of human melanocytes, 
established primary and metastatic melanoma cell lines. Immunoblot 
analysis revealed constitutive, yet differential MX2 protein expression 
that correlated with RNA levels (Figure 1a,b). Most metastatic lines 
expressed lower levels of MX2 compared to the primary melanoma 
and cultured melanocyte lines. Furthermore, an apparent reduction 
of MX2 protein level was seen in metastatic WM239 line compared 
to primary WM115 line, both derived from the same patient, suggest‐
ing that MX2 is downregulated during disease progression.
Interestingly, the highest MX2 protein expression was seen in the 
recently established early passage metastatic MM382 line. To rule 
out that this could be an in vitro culturing artifact, we also examined 
MX2 expression in the original tumor sample that was histologically 
dissected and evaluated to contain more than 80% of tumor cells, 
and found it to be comparable to the cell line (Figure 1c,d). Variable 
expression of MX2 RNA was also observed in 45 fresh metastatic 
melanoma tumor samples, derived from lymph nodes. The majority 
(31/45) of samples had lower relative RNA levels when normalized 
to primary WM1366 cell line (Figure 1e). Furthermore, there was 
no statistically significant difference in MX2 expression between 
BRAFV600E mutant and wild‐type samples (Table S2).
We also investigated whether rs45430 SNP is associated with 
MX2 expression in both cell lines and metastatic melanoma samples 
(Figure 1a,e). While we observed a tendency for TT genotype to 
be associated with a higher MX2 expression, it was not statistically 
significant.
In other cell types, MX2 expression is shown to be induced by 
IFN signaling. To examine whether this is valid in melanoma, we in‐
cubated the low and high MX2 expressing cell lines WM983b and 
MM382 with IFNα or IFNγ for 24h. IFNα/γ treatment resulted in up‐
regulation of both RNA and protein MX2 level (Figure 1f and Figure 
S1a), confirming that MX2 is an IFN response gene in melanoma, 
though it can also be constitutively expressed independently of INF 
stimulation.
We also examined possible association between MX2 expression 
and related MX1, in the same cell lines and tumor samples. We ob‐
served no correlation between MX2 and MX1 protein (Figure S1b) 
and mRNA expression (Figure S1c,d) in the cell lines. However, in 
tumor samples MX2 and MX1 mRNA expression significantly cor‐
related, possibly due to the contribution of microenvironment‐de‐
rived IFN (Figure S1e,f).
Antiviral functions of MX2 have been associated with its lo‐
calization to the nuclear envelope; however, cytoplasmic localiza‐
tion has also been reported (Dicks et al., 2018; Melén et al., 1996). 
Cytoplasmic and nuclear fractionation of melanoma cell lines showed 
that MX2 protein is mainly found in the nuclear fraction, but a weak 
cytoplasmic localization was also detected (Figure 1g).
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3.2 | MX2 expression is associated with longer 
melanoma‐specific survival
Using previously described whole transcriptome data derived from 
703 primary melanomas from the Leeds Melanoma Cohort (LMC) 
(Nsengimana et al., 2018), we investigated the expression and asso‐
ciation of MX2 mRNA level with melanoma‐specific survival (MSS). 
A Kaplan–Meier curve was generated after dichotomization of MX2 
expression to high and low groups with respect to the median show‐
ing that higher MX2 expression was associated with longer mela‐
noma‐specific survival (HR = 0.8, p = .004) (Figure 2a). Similar results 
were observed in the TCGA melanoma metastases—application of 
Cox proportional hazards model after median‐based dichotomiza‐
tion revealed that high MX2 expression was associated with better 
overall patient survival (N = 339, HR = 0.7, p = .026) (Figure 2b).
Furthermore, weak yet significant negative correlation was ob‐
served between MX2 expression and Breslow thickness (R = −0.2, 
p = 5.4 × 10–8) as well as MX2 and the mitotic rate (R = −0.13, 
p = .002) in the LMC (Figure S2a and b).
Since interferon signaling, which might induce MX2, is involved 
in immune cell infiltration in tumors, we analyzed MX2 expression in 
the LMC stratified by strength of immune signal resulting in three 
immune subgroups. The generation of the immune subgroups was 
defined in Poźniak et al., (2019). MX2 expression was significantly 
lowest in the low immune and highest in the high immune subgroup 
(Figure 2c). Comparable results were seen in the TCGA melanoma 
metastases cohort (Figure S2c).
The analysis of LMC also showed associations between MX2 
expression and histologically detected tumor‐infiltrating lympho‐
cytes (TILs) (Figure S2d). MX2 expression was significantly higher in 
tumors with TILs in comparison with tumors that had no TILs. We 
then compared the association between MX2 expression and MSS 
in the LMC primary tumors stratified by strength of immune sig‐
nal. MX2 expression was borderline protective in the low immune 
subgroup. The results for the intermediate and high immune sub‐
groups were not significant but show similar estimates of the haz‐
ard ratio so their lack of significance may simply reflect relatively 
small sample size (Table 1). There was no association between MX2 
F I G U R E  1   Characterization of MX2 expression. (a) The analysis of MX2 protein expression by immunoblotting (β‐actin used as a loading 
control). BRAF V600E and rs45430 status specified under the cell names: ND—not determined, WT—wild type, +—mutation is present. (b) 
MX2 mRNA expression in normal human melanocytes (NHM), and primary and metastatic melanoma lines (mRNA expression is presented 
as a mean value ± SE of three independent experiments). MX2 mRNA expression is normalized to primary melanoma WM1366 cell line. 
(c) Comparison of MX2 protein expression in established melanoma WM382 line and original tumor sample by immunoblotting and (d) 
immunohistochemistry. (e) MX2 mRNA expression in metastatic melanoma tumor samples. Tumors expressing lower MX2 mRNA levels 
compared to primary WM1366 are inside the dashed rectangle. Columns are colored according to rs45430 genotype. (f) Increase of MX2 
mRNA and protein expression after treatment with IFNα 1,000 IU/ml for 24 hr (mRNA expression is presented as a mean value ± SE of 
three independent experiments). (g) Cytoplasmic and nuclear expression of MX2 in normal human melanocytes, and primary and metastatic 
melanoma cell lines examined by immunoblotting. Each MX2 blot was visualized separately
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expression and MSS in the TCGA stratified by immune status (data 
not shown).
We also tested whether rs45430 SNP is associated with MX2 
expression in the primary melanomas. The SNP data were generated 
as previously described (Law et al., 2015). The expression of MX2 
was significantly lower in participants homozygous for the C allele in 
comparison with the CT or TT genotype (Figure 2d).
Protein expression of MX2 was also analyzed by immunohis‐
tochemistry in a second melanoma dataset consisting of 42 par‐
affin‐embedded nevi, 154 primary melanomas, and 60 metastatic 
melanomas. As shown in Figure 2e, cytoplasmic and/or nuclear 
expression was observed. Note that a variable MX2 staining was 
also observed in infiltrating immune cells.
Comparably high MX2 expression (immunoscore >3) was seen 
in nevi (21.4%), primaries (26.6%), and metastases (24%). However, 
complete lack of immunoreactivity was observed in 2.4% nevi, 7.8% 
primary, and 15% metastatic tumors, respectively, suggesting that 
MX2 is downregulated during disease progression in a proportion 
of tumors. The analysis of disease‐specific and progression‐free 
survival in this cohort showed no significant correlation with MX2 
expression. There was a significant positive correlation observed be‐
tween MX2 expression and extent of tumor‐infiltrating immune cells 
in the tumors (R = 0.23, p = .008).
3.3 | Overexpression of MX2 reduces melanoma 
proliferation by reducing activation of the PI3K/
AKT pathway
To further investigate the functional role of MX2 in melanoma, we 
stably overexpressed MX2 in normal human melanocytes NHM134, 
NRAS mutant WM1366, and BRAF mutant metastatic WM983b cell 
line. To develop a stable melanocyte cell line expressing MX2 or 
F I G U R E  2   Expression of MX2 is 
associated with a better melanoma‐
specific survival. (a) Kaplan–Meier 
melanoma‐specific survival analysis of 
703 primary melanomas and (b) Kaplan–
Meier overall survival analysis of 339 
TCGA metastatic melanomas stratified 
by median MX2 RNA expression where 
low is defined as bellow median. The 
analysis performed applying univariate 
Cox proportional hazard model. (c) MX2 
RNA expression in high, intermediate, and 
low immune subgroups. (d) Expression 
quantitative trait loci (eQTL) analysis of 
MX2 gene single nucleotide polymorphism 
rs45430 in 703 primary melanomas (e) 
Representative immunohistochemistry 
staining of MX2 in (1) nevi, (2) primary, 
and (3 and 4) metastatic melanoma
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TA B L E  1   Association between MX2 expression and MSS in the 
LMC primary tumors stratified by the strength of immune signal
Subgroup stratified by the 
strength of immune signal HR p 95% CI
Whole dataset (N = 703) 0.80 .004 0.69–0.93
Low immune (N = 268) 0.83 .064 0.69–1.01
Intermediate immune (N = 256) 0.92 .626 0.65–1.29
High immune (N = 144) 1.11 .765 0.56–2.19
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GFP, we used the Tet‐On doxycycline‐inducible system. As shown 
in Figure 3a, a clear increase in MX2 protein levels was observed 
in all cell lines after selection or induction when compared to GFP 
expressing control vector‐transfected cells. In vitro effects of in‐
creased MX2 protein levels on proliferation were assessed using 
IncuCyte™ analyzing the area occupied by the cells (% confluence). 
The relative confluence of cells growing under normal conditions for 
72 hr was significantly reduced in MX2 overexpressing WM1366 
and WM983b cells compared to their respective GFP controls 
(Figure 3b). This inhibitory growth effect was not observed in nor‐
mal melanocytes. No visibly detectable phenotypical changes were 
observed in the engineered melanocytes overexpressing GFP and 
MX2 (Supporting Figure S3a). Furthermore, we found no effects 
on expression of melanocyte differentiation markers Melan‐A and 
MITF (Figure S3b).
To study whether the effect of MX2 overexpression was relevant 
for tumor formation in vivo, WM983b and WM1366 cells overex‐
pressing MX2 or control protein GFP were subcutaneously injected 
into the right flank of athymic nude mice. As shown in Figure 3 pan‐
els c and d, overexpression of MX2 significantly suppressed tumor 
growth compared to GFP control group of WM983b cells. WM1366 
MX2 and GFP expressing cells displayed poor in vivo growth proper‐
ties, and no tumor growth was detected for up to 50 days.
In an attempt to explain the observed MX2 growth inhibitory 
effects, we analyzed known survival and proliferation signaling 
pathways including the MAPK and AKT pathways in extracted 
tumor xenograft lysates. We found that overexpression of MX2 
led to reduced phosphorylation of AKT regulatory residues Thr308 
and Ser473, decreased levels of AKT downstream phosphoprotein 
GSK3β, and a minor increase in PTEN protein levels, suggesting that 
the activity of the pathway is reduced. Furthermore, we observed el‐
evated expression levels of Wee1 and the tumor suppressor p21Cip1 
(Figure 3e) suggesting abrogation of the cell cycle. We did not ob‐
serve significant changes to the MAPK pathway. The same results 
were obtained in vitro for both WM1366 and WM983b cells (Figure 
S3c) suggesting that MX2 contributes to the regulation of the cell 
cycle and proliferation, displaying tumor suppressor features.
3.4 | MX2 function in melanoma is cell line‐
dependent
Since we observed that a subset of melanoma cell lines displays 
high constitutive MX2 expression, it is possible that these cells have 
adapted to circumvent its growth inhibitory effects or that MX2 has 
a different functional role in these cells. To investigate these pos‐
sibilities, we downregulated MX2 using two different MX2 target‐
ing siRNA oligos. A clear reduction in MX2 mRNA levels was seen 
after siRNA transfection without effecting MX1 (Figure S4a,b). 
Interestingly, 72 hr post‐transfection, a significant viability decrease 
was seen in high MX2 expressing WM115 and MM382 cells, while 
subtle or no effects were seen in low MX2 expressing WM1366 cells 
(Figure 4a). To identify whether the observed decrease in viability 
was due to decreased proliferation or apoptosis, we examined the 
expression of mitosis marker phospho‐Histone H3 (pHH3) and the 
F I G U R E  3   MX2 overexpression inhibits melanoma cell growth both in vitro and in vivo. (a) Immunoblot analysis of MX2 protein 
expression in normal human melanocytes and melanoma cells after lentiviral transduction. Tet‐On system was used to achieve doxycycline‐
inducible expression of MX2 and GFP in normal human melanocytes. Increased MX2 protein expression seen in melanocytes after 
administration of 500 ng/ml doxycycline for 48 hr and stable expression in melanoma lines. (b) Growth curves of cells overexpressing GFP 
or MX2 were obtained using IncuCyte Zoom live‐cell imaging system. Curves represent fold increase of cell growth versus time at 3‐hr 
intervals. Results are expressed as mean ± SE of three independent experiments. Wilcoxon matched‐pairs signed‐rank test was used for 
comparison between the groups. Statistically significant results are marked with asterisk, *** p < .001. (c) Image of harvested tumors at 
day 50 post‐subcutaneous injection of 2 × 106 WM983b cells stably expressing GFP or MX2. (d) Tumor volume at day 50 after injection. 
t test was applied to assess significance. (e) Assessment of AKT pathway activity by immunoblotting in lysates of the xenograft tumors 
overexpressing MX2 or GFP
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apoptotic marker‐cleaved caspase 3. As seen in Figure 4b, no nota‐
ble increase in caspase 3 cleavage was observed in any of the cell 
lines following MX2 downregulation, while a clear reduction in phos‐
phorylation of HH3 at serine 10 was evident in WM115 and MM382 
suggesting cell cycle‐related effect in these lines. The activation of 
the AKT and MAPK signaling pathways was also examined, but sur‐
prisingly no significant changes were observed (Figure S5).
Effects of MX2 downregulation on the cell cycle distribution 
were assessed by flow cytometry 48 hr post‐siRNA transfections. 
The analysis revealed that MX2 knockdown increased the propor‐
tion of cells in G1 phase, including weak effect in WM1366 sug‐
gesting induction of the cell cycle arrest (Figure 4c). As expected, 
G1 arrest was accompanied with decreased levels of cyclin D1 and 
kinase Cdk2 expression and increased levels of Cdk inhibitory pro‐
teins p27Kip1 and p21Cip1 (Figure 4d). Again, observed effects were 
more prominent in WM115 and MM382 cell lines than in WM1366.
Due to these notable effects on the cell cycle, we investigated 
whether MX2 expression itself could be oscillating during the cycle. 
Synchronization of the cells at G1/S boundary by double thymidine 
block showed expected oscillation of the cyclins and mitotic phos‐
pho‐Histone H3 after release. MX2 levels, however, did not change 
during the cell cycle progression suggesting that its expression is cell 
cycle phase‐independent (Figure 4f).
To further investigate which cellular processes are influenced by 
MX2 downregulation, we also performed RNA‐seq of MM382 cells 
48 hr after siRNA transfection. A core of 520 differentially expressed 
genes (Table S3) overlapping between two siRNA oligos was selected 
for further GO enrichment analysis (Figure 5a), while fifty most up‐ 
and downregulated genes are presented in Figure 5b. The analysis 
showed that highly over‐represented GO terms included processes 
involved in cell cycle regulation and progression (Figure 5c). Among 
significantly downregulated genes after MX2 downregulation was 
a major mitotic protein kinase Aurora A. The validation of RNA‐seq 
data by Western blot indeed confirmed that in WM115 and MM382 
lines Aurora A and its downstream target PLK1, which control cen‐
trosome maturation and spindle assembly at G2/M transition, are 
downregulated following MX2 siRNA transfection (Figure 5d). As a 
result, protein levels of downstream members of Aurora A—PLK1 
F I G U R E  4   MX2 downregulation perturbs cell cycle and reduces proliferation in a subset of melanoma lines. (a) Trypan Blue dye exclusion 
viability test 72 hr post‐transfection with two independent siRNAs for MX2 (#1 siMX2 and #2 siMX2) and negative control (siCTR). Viability 
counts are normalized to negative control. Results are expressed as mean ± SE of three independent experiments. Two‐tailed paired t 
test was used to test statistical significance. * p < .05. (b) Immunoblot analysis of affected apoptosis and proliferation‐associated proteins 
upon MX2 knockdown. GAPDH was used as a loading control. (c) Evaluation of cell cycle distribution by flow cytometry using propidium 
iodide staining. Cells were transfected with #1 siMX2, #2 siMX2, and siCTR 48 hr prior to flow cytometric analysis. Bar graphs represent 
percentages of cells in different cell cycle phases (average from three independent experiments ± SE). (d) Immunoblot analysis of proteins 
involved in G1/S transition of the cell cycle. (e) Oscillation of MX2 protein level during cell cycle was examined by releasing MM382 cells 
synchronized in G1/S phase from double thymidine block
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axis, including cdc25c and cyclin B1, were also reduced leading to 
impeded progression through G2/M. Jointly, our data suggest that 
even if MX2 is downregulated in metastatic samples and displays 
tumor‐suppressive function in the majority of melanoma lines, in a 
subset of melanomas, it displays proto‐oncogenic features and is an 
important factor necessary for cell cycle regulation and proliferation 
of these cells.
4  | DISCUSSION
In recent years, several GWAS have identified novel melanoma 
susceptibility SNPs, including in the intron of MX2 gene that have 
no previously defined functional roles in cancer‐related processes. 
Thus, the overall objective of our study was to investigate whether 
and how MX2 function can influence melanoma tumorigenesis. So 
far, MX2 has been mainly defined by its antiviral functions, high‐
lighting its induction by type I IFN and ability to interfere with the 
replication of different types of negative‐stranded RNA viruses. 
Our expression data from melanocytes, and primary and metastatic 
melanoma show that MX2 can be constitutively expressed indepen‐
dently of IFN induction, which is in agreement with two previous 
studies in HeLa and T98G cells (King et al., 2004; Melén et al., 1996).
While we detected MX2 expression in all melanocyte and pri‐
mary melanoma cell lines, 8 out of 10 metastatic cell lines showed 
lower or lack of expression. There was also an apparent reduction 
of expression in a metastatic versus primary cell line derived from 
the same patient suggesting that MX2 is downregulated during 
disease progression. Furthermore, an increasing percentage of 
MX2 IHC negative samples was observed in metastatic lesions. 
The exact mechanism of this downregulation needs further elu‐
cidation, but inactivation of the IFN pathway and suppression of 
its target genes during disease development has been reported 
in melanoma as well as in other cancers (Katlinskaya et al., 2016; 
Katlinski et al., 2017; Walter et al., 2017). Interestingly, a study 
of breast cancer by Han et al. (Han, Russo, Kohwi, & Kohwi‐
Shigematsu, 2008) found that transcription factor and chromatin 
organizer SATB1 reprograms gene expression profile of cancer 
cells to promote tumor growth and that MX2 is among the re‐
pressed genes.
Here, we also showed that reintroduction of MX2 expression 
in endogenously low expressing cell lines leads to downregulation 
of AKT activity and inhibition of tumor growth in vitro and in vivo. 
These effects were profound in a metastatic WM983b suggesting 
that downregulation of MX2 is important during disease progres‐
sion. Since it is demonstrated that type I and II IFNs used in mela‐
noma treatment due to their antiproliferative effects can regulate 
AKT activity in a complex manner (Kaur, Sassano, Dolniak, et al., 
2008; Kaur, Sassano, Joseph, et al., 2008), one can speculate if some 
of these effects can partially be mediated by MX2.
F I G U R E  5   Gene expression analysis 
of MM382 melanoma cells after MX2 
siRNA transfection (a) Venn diagram of 
differentially expressed genes (DEGs) 
between #1 siMX2, #2 siMX2, and 
siCTR. Pink circle represents the number 
of genes with different expression 
levels between #1 siMX2 versus siCTR. 
Green circle represents the number of 
genes with different expression levels 
between #2 siMX2 versus siCTR. Blue 
circle represents the number of genes 
with different expression levels between 
#1 siMX2 and #2 siMX2 versus siCTR. 
(b) Heatmap of 25 most upregulated 
(green) and downregulated (red) genes. 
(c) GO enrichment analysis of biological 
processes for the 520 differentially 
expressed genes overlapping between 
#1 siMX2 and #2 siMX2. (d) Validation 
of RNA‐seq transcriptome analysis by 
immunoblotting
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The analysis of transcriptomic data from the Leeds Melanoma 
Cohort of 703 tumors and TCGA metastases showed that high ex‐
pression of MX2 mRNA was associated with better prognosis. We 
did not observe similar effects of protein expression in our second 
validation cohort, which might be due to much smaller sample size. It 
is difficult to exclude the possibility that a significant component of 
the MX2 gene expression signal in the Leeds Melanoma Cohort is de‐
rived from TILs which themselves are a favorable prognostic marker 
in melanoma (Fu et al., 2019). The expression of MX2 in tumor cells 
did, however, correlate with the amount of immune cell infiltration im‐
plying that IFN secretion by TILs leads to induction of MX2 and other 
IFN‐dependent genes like MX1. Indeed, we did observe a correlation 
between MX2 and MX1 expression in tumor samples. However, we 
did not see such correlation in our panel of cell lines, suggesting that 
even though IFNs are major regulatory factors of MX2, there are also 
other mechanisms involved. For instance, a recent study by Punia et al. 
found that Engrailed‐2 (EN2) transcription factor secreted by prostate 
tumors can induce MX2 expression in stromal cells (Punia, Primon, 
Simpson, Pandha, & Morgan, 2019), and MX2 was a single gene show‐
ing a dose–response relationship to recombinant EN2 treatment.
Interestingly, the observation that MX2 expression is borderline 
protective even in the low immune subgroup combined with the fact 
that some tumors display high MX2 immunoreactivity while lacking 
TILs, argues for its immune‐independent functions. Jointly, these 
results support the hypothesis that MX2 has tumor‐suppressive fea‐
tures in melanoma.
Inheritance of the minor C allele rs45430 SNP in the intron 
of MX2 was reported to be protective for melanoma and multiple 
primaries in the GWAS (Barrett et al., 2011; Gibbs et al., 2015). Here, 
we found that the homozygous C allele is associated with lower ex‐
pression of MX2 in primary melanoma tumors, and a similar trend 
was seen in metastatic samples. Since we also report that higher ex‐
pression levels of MX2 are seen in thinner primaries with a lower mi‐
totic rate and better survival, these data seem somewhat difficult to 
explain. However, it is known that expression quantitative trait loci 
(eQTL) can display opposite directional effects in a tissue‐specific 
manner (Mizuno & Okada, 2019). Indeed, minor C allele is associated 
with lower MX2 expression in whole blood, while the opposite is 
seen for sun‐exposed skin (Figure S6) (TheGTExConsortium, 2015). 
Currently, it is unclear what functional role MX2 plays in different 
immune cell types or how this relates to melanoma risk; therefore, 
further studies are warranted.
Interestingly, we have observed similar discrepancies previously 
for an inherited SNP in the PARP1 gene. The SNP was associated 
with higher PARP1 levels, increased risk of melanoma, and related 
to PARP1 induced cell proliferation mediated through MITF (Choi et 
al., 2017). Yet, the same SNP was found to be associated with a lower 
risk of death from melanoma (Davies et al., 2014).
Remarkably, despite its growth inhibitory effects and down‐
regulation in metastatic cell lines, a subset of melanoma lines in 
our panel exhibited high endogenous MX2 expression. Knockdown 
of MX2 in these lines decreased proliferation and lead to pertur‐
bation of the cell cycle, which is inconsistent with observations 
from our overexpression experiments. However, MX2 belongs to 
dynamin‐like GTPase family proteins, which are also known to be 
involved in the regulation of cell cycle progression and it is likely 
that MX2 function is complex and cell type‐ and context‐depen‐
dent. In support of these observations, one previous study has re‐
ported that depletion of endogenous MX2 in cancer cells results in 
delayed progression through G1/S phase of the cell cycle (King et 
al., 2004). We have observed similar G1 arrest accompanied with 
cyclin D1 degradation and cyclin E upregulation in p21‐dependent 
manner as reported (Sandor et al., 2000). In addition, our RNA‐seq 
analysis revealed that MX2 is also involved in DNA replication and 
mitosis processes partially by regulation of Aurora A and PKL1. A 
study by Kane et al. (2013) investigating MX2 potency to inhibit 
HIV‐1 showed that arresting the cell cycle in osteosarcoma and 
myelogenous leukemia cells increases MX2 viral inhibitory activ‐
ity. We can speculate that antiviral MX2 potency in non‐dividing 
cells increases when it does not engage in other cellular processes, 
including DNA replication and/or mitosis as suggested by our 
study. These results further support the hypothesis of a cellular 
type‐ and setting‐dependent MX2 function.
In summary, we have demonstrated that widely accepted antivi‐
ral MX2 gene has tumor‐suppressive features in melanoma, where 
it regulates the growth of tumor cells partially through negative 
modification of AKT activity, and it is downregulated during disease 
progression. However, its role seems to be complex and cell context‐
dependent since we found that in a subset of melanoma cell lines, it 
is highly expressed and necessary for cell cycle progression. Further 
elucidation of this dual mechanism of action is needed to understand 
its complex roles in tumorigenesis.
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